Innovent and iaso bio jointly announce the nmpa acceptance of the new drug application for equecabtagene autoleucel for the treatment of relapsed and/or refractory multiple myeloma

San francisco and suzhou, china , june 5, 2022  /prnewswire/ -- innovent biologics, inc. ("innovent") (hkex: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and iaso biotherapeutics ("iaso bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the china national medical products administration (nmpa) has formally accepted the new drug application (nda) for equecabtagene autoleucel (innovent r&d code: ibi326，iaso bio r&d code: ct103a) , a fully human anti-b cell maturation antigen (bcma) chimeric antigen receptor (car) t-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (r/r mm). equecabtagene autoleucel is the first car-t therapy in china that is self-developed with proprietary whole-process product development and the first bcma-targeting car t-cell therapy in china with its nda formally accepted by the nmpa.
SANA Ratings Summary
SANA Quant Ranking